Evidence map›Paper›PMID 33091368›Full record

ArticleCell stem cell2021

Non-canonical Targets of HIF1a Impair Oligodendrocyte Progenitor Cell Function.

Kevin C Allan, Lucille R Hu, Marissa A Scavuzzo, Andrew R Morton, Artur S Gevorgyan, Erin F Cohn, Benjamin L L Clayton, Ilya R Bederman, Stevephen Hung, Cynthia F Bartels and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cell stem cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kevin C AllanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Lucille R HuDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Marissa A ScavuzzoDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Andrew R MortonDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Artur S GevorgyanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Erin F CohnDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Benjamin L L ClaytonDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Ilya R BedermanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Stevephen HungDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Cynthia F BartelsDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Mayur MadhavanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Paul J TesarDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Electronic address: paul.tesar@case.edu.
University School · USCase Western Reserve University · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Targeting the integrated stress response to protect oligodendrocyte lineage cells - Resubmission 01R01NS034939 · NINDS · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI POPKO, BRIAN J · 1997 to 2024
$7.5M
Modulating Glial Fate and Function in Development and DiseaseR35NS116842 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI Paul Joseph Tesar · 2020 to 2026
$5.3M
Training in Neurodegenerative DiseasesT32NS077888 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI Xiongwei Zhu · 2013 to 2026
$1.8M
Acquisition of a Leica TCS SP5 Confocal Microscope For A Multi-User FacilityS10OD016164 · OD · CASE WESTERN RESERVE UNIVERSITY · PI CONRAD, PATRICIA A · 2013 to 2013
$597k
Hamamatsu Nanozoomer S60 Digital Whole Slide ScannerS10OD024981 · OD · CASE WESTERN RESERVE UNIVERSITY · PI IMANISHI, YOSHIKAZU · 2018 to 2018
$303k
Mechanism of hypoxia mediated failure of oligodendrocyte generationF30HD096784 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI ALLAN, KEVIN CAMERON · 2019 to 2022
$163k
NCI NIH HHS P30 CA043703NICHD NIH HHS F30 HD096784NIGMS NIH HHS T32 GM007250NIH HHS S10 OD016164NIH HHS S10 OD024981NINDS NIH HHS R01 NS034939NINDS NIH HHS R35 NS116842NINDS NIH HHS T32 NS077888
6 · The paper itself

Abstract

Mammalian cells respond to insufficient oxygen through transcriptional regulators called hypoxia-inducible factors (HIFs). Although transiently protective, prolonged HIF activity drives distinct pathological responses in different tissues. Using a model of chronic HIF1a accumulation in pluripotent-stem-cell-derived oligodendrocyte progenitors (OPCs), we demonstrate that HIF1a activates non-canonical targets to impair generation of oligodendrocytes from OPCs. HIF1a activated a unique set of genes in OPCs through interaction with the OPC-specific transcription factor OLIG2. Non-canonical targets, including Ascl2 and Dlx3, were sufficient to block differentiation through suppression of the oligodendrocyte regulator Sox10. Chemical screening revealed that inhibition of MEK/ERK signaling overcame the HIF1a-mediated block in oligodendrocyte generation by restoring Sox10 expression without affecting canonical HIF1a activity. MEK/ERK inhibition also drove oligodendrocyte formation in hypoxic regions of human oligocortical spheroids. This work defines mechanisms by which HIF1a impairs oligodendrocyte formation and establishes that cell-type-specific HIF1a targets perturb cell function in response to low oxygen.

Indexed as

Oligodendrocyte Precursor CellsPluripotent Stem CellsAnimalsBasic Helix-Loop-Helix ProteinsCell DifferentiationCells, CulturedHumansHypoxia-Inducible Factor 1, alpha SubunitOligodendrogliaASCL2 protein, humanBasic Helix-Loop-Helix ProteinsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitdifferentiationHIF1ahypoxiaoligodendrocyte progenitor cellsOPCs

Identifiers

PMID33091368
PMCPMC7867598
OpenAlexW3094079459

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.